Throughout the last three months, 19 analysts have evaluated Biogen (NASDAQ:BIIB), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 5 | 7 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 4 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 7 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.32, a high estimate of $342.00, and a low estimate of $200.00. This current average has decreased by 2.86% from the previous average price target of $282.39.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Biogen among financial experts is revealed through an in-depth...
Login or create a forever free account to read this news
Sign up/Log in